Skip to content
Saturday, March 15, 2025
GLP-1 Watch
All the latest news and updates about GLP-1 Drugs
Search
Search
Privacy Policy
The Evolving Landscape of GLP-1 Drugs: Innovations, Market Trends, and Health Implications
Home
2025
March
7
FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKD
GLP-1 News
FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKD
March 7, 2025
admin
The US FDA has approved scPharmaceuticals’ sNDA for Furoscix, expanding its indication to include oedema treatment in individuals with CKD.
Post navigation
Pfizer appoints former J&J executive to lead obesity drug development – Reuters
New Discovery Promises Weight Loss Without Ozempic’s Side Effects – Newsweek